Authorized purpose: QuantX is breast MRI software for the labeled management, analysis, visualization, and decision-support workflow; exact image inputs, outputs, and use remain submission-specific.
Clinical role
Breast MRI image analysis, visualization, or decision support as an adjunct to physician interpretation.
Images and patients
MRI · Breast
Key limitation
Keep in mind: Exact MRI sequence, contrast, anatomy, patient population, image quality, and review workflow limits require submission-specific labeling. QuantX is breast MRI software for the labeled management, analysis, visualization, and decision-support workflow; exact image inputs, outputs, and use remain submission-specific.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: QuantX is breast MRI software for the labeled management, analysis, visualization, and decision-support workflow; exact image inputs, outputs, and use remain submission-specific.
Which images or clinical context are in scope?Modality: MRI Anatomy or clinical context: Breast Input: Supported breast MRI images and release-specific DICOM metadata.
Who uses it?Intended users: Qualified radiologists and trained breast-imaging professionals.
What does the software produce?Output: Breast MRI analysis, visualization, measurements, or decision-support outputs for professional review.
What is its most important limitation?Key limitation: Exact MRI sequence, contrast, anatomy, patient population, image quality, and review workflow limits require submission-specific labeling. QuantX is breast MRI software for the labeled management, analysis, visualization, and decision-support workflow; exact image inputs, outputs, and use remain submission-specific.
Clinical takeaway. Clinical role: QuantX is breast MRI software for the labeled management, analysis, visualization, and decision-support workflow; exact image inputs, outputs, and use remain submission-specific.
Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports standalone AUC of 0.86 ± 0.02 by bootstrap on the Similar Case Database (training database), which cannot be considered independent validation, and 0.75 ± 0.05 on the reader study testing database with automated segmentation. In an MRMC study, 19 readers read 111 breast MR cases; the second-read minus first-read AUC difference was 0.0520 (95% CI [0.0022, 0.1018]), and the document states the study marginally met the primary endpoint. Results are as reported in the FDA submission, not independent validation.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
QuantX is breast MRI software for the labeled management, analysis, visualization, and decision-support workflow; exact image inputs, outputs, and use remain submission-specific.
Exact MRI sequence, contrast, anatomy, patient population, image quality, and review workflow limits require submission-specific labeling. QuantX is breast MRI software for the labeled management, analysis, visualization, and decision-support workflow; exact image inputs, outputs, and use remain submission-specific.
The exact FDA document reports standalone AUC of 0.86 ± 0.02 by bootstrap on the Similar Case Database (training database), which cannot be considered independent validation, and 0.75 ± 0.05 on the reader study testing database with automated segmentation. In an MRMC study, 19 readers read 111 breast MR cases; the second-read minus first-read AUC difference was 0.0520 (95% CI [0.0022, 0.1018]), and the document states the study marginally met the primary endpoint. Results are as reported in the FDA submission, not independent validation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Overall AUC performance based on the bootstrap method was 0.86 ± 0.02 (mean ± standard error) Study limitation: The standalone study that used the Similar Case Database (i.e., training database) cannot be considered an independent validation study" … "Overall AUC performance based on the reader study testing database using the automated segmentation without manual input was 0.75 ± 0.05 (mean ± standard error).". Read from the exact FDA decision document on 2026-11-14.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
The exact FDA document reports standalone AUC of 0.86 ± 0.02 by bootstrap on the Similar Case Database (training database), which cannot be considered independent validation, and 0.75 ± 0.05 on the reader study testing database with automated segmentation. In an MRMC study, 19 readers read 111 breast MR cases; the second-read minus first-read AUC difference was 0.0520 (95% CI [0.0022, 0.1018]), and the document states the study marginally met the primary endpoint. Results are as reported in the FDA submission, not independent validation.
FDA source
Exact FDA submission
Checked 2026-11-14
Packet wording: "Overall AUC performance based on the bootstrap method was 0.86 ± 0.02 (mean ± standard error) Study limitation: The standalone study that used the Similar Case Database (i.e., training database) cannot be considered an independent validation study" … "Overall AUC performance based on the reader study testing database using the automated segmentation without manual input was 0.75 ± 0.05 (mean ± standard error).". Read from the exact FDA decision document on 2026-11-14.
No exact submission and version-linked sensitivity endpoint is published in this dossier; do not substitute a product-family or candidate-study value.
Reported specificity
Not established in reviewed sources
Reviewed sources checked
Exact FDA submission
Checked 2026-09-04
No exact submission and version-linked specificity endpoint is published in this dossier; do not substitute a product-family or candidate-study value.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
FDA submission-specific verification and validation evidence for DEN170022
DesignRegulatory verification, validation, and labeling evidence reviewed for exact FDA submission DEN170022.
PopulationThe labeled population and test materials for exact submission DEN170022; a general clinical study population is not established here.
Scopeexact submission
Tested versionQuantX (DEN170022)
IndependenceSponsor or vendor study
DEN170022
FDA regulatory evidence is submission-specific but is not independent clinical performance evidence.
3 unlinked candidate evidence records are retained for source review and excluded from this evidence display.
Safety and lifecycle
Postmarket record
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
Not established in reviewed sources
Reviewed sources checked
Exact FDA submission
Checked 2026-09-04
No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.
Pricing & contractsPublic price, contract terms, and reimbursement
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Supported breast MRI images and release-specific DICOM metadata.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The exact FDA package describes QuantX loading MR images from a third-party acquisition device manually or automatically when connected to a DICOM-compatible device, with tools to measure and document images and output in a structured report. Interface versions and local compatibility require confirmation.
Scope: Exact FDA submission. Packet wording: "MR images are acquired from a third-party acquisition device. The images can be loaded into the QuantX device manually or automatically if connected to a DICOM- compatible device." … "The software also includes tools that allow users to measure and document images, and output in a structured report.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Unresolved route: Not established for the exact route.
Scope: Exact FDA submission. Exact deployment topology, hosting, network boundaries, update mechanism, and local operational requirements are not established for this submission.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-09-04 ·
Returned objects
Source context, not route validation: Breast MRI analysis, visualization, measurements, or decision-support outputs for professional review.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Breast MRI analysis, visualization, measurements, or decision-support outputs for professional review.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes QuantX loading MR images from a third-party acquisition device manually or automatically when connected to a DICOM-compatible device, with tools to measure and document images and output in a structured report. Interface versions and local compatibility require confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "MR images are acquired from a third-party acquisition device. The images can be loaded into the QuantX device manually or automatically if connected to a DICOM- compatible device." … "The software also includes tools that allow users to measure and document images, and output in a structured report.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Current vendor material is product-family context for DEN170022 only; exact release, enabled options, deployment, and local interoperability require confirmation.
product family · checked 2026-09-04
Vendor material is not exact-release evidence unless that linkage is separately proven.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
28Fields reviewed
14Source classes checked
1Screened PubMed leads
3Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains 1 PubMed and 3 ClinicalTrials.gov candidate records. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 1 PubMed and 3 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, vendor product page, implementation documentation, reimbursement policy, peer reviewed literature, clinical trial registry, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission
No public exact-release price, license fee, subscription, contract, or implementation cost was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not applicable - checked 2026-09-04 - Not applicable
CMS index context was checked, but no product-specific coverage or reimbursement determination is inferred.
Deployment: Not publicly available - checked 2026-09-04 - Exact FDA submission
Exact deployment topology, hosting, network boundaries, update mechanism, and local operational requirements are not established for this submission.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not publicly available - checked 2026-09-04 - Exact FDA submission
Public sources reviewed here do not establish the complete exact-release security posture, including identity, audit, encryption, retention, remote access, vulnerability management, backup, or incident response.
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-10-27 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-10-27 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Authorized purpose: TumorSight Viz processes dynamic contrast-enhanced breast MRI for patients with biopsy-proven early-stage or locally advanced breast cancer, providing registration, subtraction, segmentation, 3D renderings, measurements, kinetic curves, parametric maps, MIPs, and reformats for physician visualization and analysis; results are not the sole basis for patient management.
Authorized purpose: Visualize and analyze DCE breast MRI studies for patients with biopsy-proven early-stage or locally advanced breast cancer, including processing, measurements, and configurable finding visualization; results are not a sole basis for patient management.
Modality
MRI
Anatomy
Breast, including biopsy-proven breast tumors/findings.
Authorized purpose: TumorSight Viz analyzes dynamic contrast-enhanced breast MRI for visualization and analysis of biopsy-proven early-stage or locally advanced breast cancer, including registration, subtraction, measurements, and three-dimensional views to support physician review.
Modality
MRI
Anatomy
Breast; early-stage or locally advanced breast cancer
Authorized purpose: ANDI 2.2 processes brain MR images for atlas-assisted visualization, segmentation and volumetric quantification, presenting adjunctive DICOM-readable information for trained medical professionals; it does not predict, diagnose or interpret brain health.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.